Oligonucleotide inhibition of protein kinase C
AssigneeIsis Pharmaceuticals, Inc.
InventorsC. Frank Bennett, Nicholas M. Dean, Jon T. Holmlund, F. Andrew Dorr
Life of this patent
Estimating the term…
Abstract
Compositions and methods are provided for the treatment and diagnosis of diseases associated with protein kinase C. Oligonucleotides are provided which are targeted to nucleic acids encoding PKC. In preferred embodiments, the oligonucleotides contain one or more chemical modifications. Methods of modulating PKC expression and of treating animals suffering from disease amenable to therapeutic intervention by modulating protein kinase C expression using oligonucleotides targeted to PKC are disclosed.
Claims18
A pharmaceutical composition comprising an oligonucleotide up to 50 nucleotide units in length comprising SEQ ID NO:
- 2, in combination with carboplatin and paclitaxel.
A pharmaceutical composition comprising an oligonucleotide up to 50 nucleotide units in length comprising SEQ ID NO:
- 2, in combination with docetaxel.
A pharmaceutical composition comprising an oligonucleotide up to 50 nucleotide units in length comprising SEQ ID NO:
- 2, in combination with cisplatin and gemcitabine.
A pharmaceutical composition comprising an oligonucleotide up to 50 nucleotide units in length comprising SEQ ID NO:
- 2, in combination with 5-fluorouracil and leucovorin.
A method of treating non-Hodgkin's lymphoma in a human in need thereof, comprising administering to said human a pharmaceutical composition comprising an oligonucleotide up to 50 nucleotide units in length comprising SEQ ID NO:
- 2.
Dependencies are inferred from the claim text.